REVIEW
Dystonia
Volume 4 - 2025 | doi: 10.3389/dyst.2025.14547
This article is part of the Special IssueTreatment Options in DystoniaView all 4 articles
A Narrative Review: Clinical Trials in Therapeutic Interventions for Dystonia (2020 -Present)
- 1National Institutes of Health (NIH), Bethesda, United States
- 2National Institute of Neurological Disorders and Stroke (NIH), Bethesda, Maryland, United States
- 3Department of Rehabilitation Medicine, Clinical Center (NIH), Bethesda, Maryland, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Dystonia is a disabling movement disorder affecting millions of people. Approach to managing this disorder in clinical practice include oral and intrathecal medication therapy, botulinum toxin injections, deep brain stimulation, rehabilitative regimens, or a combination of these. This paper is a comprehensive narrative journal review of the most recent clinical trials that were published or completed in the past five years or are ongoing (January 2020 to January 2025). The focus of this review it to discuss various treatment modalities and their respective outcome measure. The clinical trials described in this paper and their recent advancements are laying the foundation for future treatment trials.
Keywords: review, Dystonia, Clinical trials, Therapeutic, dystonia treatment
Received: 27 Feb 2025; Accepted: 21 Jul 2025.
Copyright: © 2025 Ly, Mushtaheed, Soliman, Karp and Cho. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Ann Ly, National Institutes of Health (NIH), Bethesda, United States
Hyun Joo Cho, National Institutes of Health (NIH), Bethesda, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.